Guangmao Yu

Dr. Guangmao Yu


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 May 2024 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
FYFuqiang Yao
Fuqiang Yao
MXMinghao Xu
Minghao Xu
LDLingjun Dong
Lingjun Dong
XSXiao Shen
Xiao Shen
YSYujie Shen
Yujie Shen
GYGuangmao Yu
Guangmao Yu
Background: Since COVID-19 became a global epidemic disease in 2019, pulmonary fibrosis (PF) has become more prevalent among persons with severe infections, with IPF being the most prevalent form. In traditional Chinese medicine, various disorders are treated using Sinomenine (SIN). The SIN’s strategy for PF defense is unclear. Methods: Bleomycin (BLM) was used to induce PF, after which inflammatory factors, lung histological alterations, and the TGF-/Smad signaling pathway were assessed. By administering various dosages of SIN and the TGF- receptor inhibitor SB-431,542 to human embryonic lung fibroblasts (HFL-1) and A549 cells, we were able to examine proliferation and migration as well as the signaling molecules implicated in Epithelial-Mesenchymal Transition (EMT) and Extra-Cellular Matrix (ECM). Results: In vivo, SIN reduced the pathological changes in the lung tissue induced by BLM, reduced the abnormal expression of inflammatory cytokines, and improved the weight and survival rate of mice. In vitro, SIN inhibited the migration and proliferation by inhibiting TGF-β1/Smad3, PI3K/Akt, and NF-κB pathways, prevented the myofibroblasts (FMT) of HFL-1, reversed the EMT of A549 cells, restored the balance of matrix metalloenzymes, and reduced the expression of ECM proteins. Conclusion: SIN attenuated PF by down-regulating TGF-β/Smad3, PI3K/Akt, and NF-κB signaling pathways, being a potential effective drug in the treatment of PF.

2 July 2024 in Frontiers in Immunology
Verified
Journal Article
Open access
PDF file
YWYuanlin Wu
Yuanlin Wu
GYGuangmao Yu
Guangmao Yu
KJKetao Jin
Ketao Jin
JQJun Qian
Jun Qian
Non-small cell lung cancer (NSCLC) remains an unsolved challenge in oncology, signifying a substantial global health burden. While considerable progress has been made in recent years through the emergence of immunotherapy modalities, such as immune checkpoint inhibitors (ICIs), monotherapies often yield limited clinical outcomes. The rationale behind combining various immunotherapeutic or other anticancer agents, the mechanistic underpinnings, and the clinical evidence supporting their utilization is crucial in NSCLC therapy. Regarding the synergistic potential of combination immunotherapies, this study aims to provide insights to help the landscape of NSCLC treatment and improve clinical outcomes. In addition, this review article discusses the challenges and considerations of combination regimens, including toxicity management and patient selection.

7 October 2022 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZLZhupeng Li
Zhupeng Li
JXJianfeng Xu
Jianfeng Xu
WFWeizhong Feng
Weizhong Feng
ZMZhifeng Ma
Zhifeng Ma
YWYuanling Wu
Yuanling Wu
GYGuangmao Yu
Guangmao Yu
To evaluate the prognostic role of the preoperative plasma lipid profile, including triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C) in patients with lung squamous cell carcinoma (LUSC) who underwent complete resection. Clinical data, including preoperative plasma profile levels, were retrospectively collected and reviewed in 300 patients with LUSC who underwent radical lung resection between 2016 and 2017. The overall survival (OS) and disease-free survival (DFS) were assessed by the Kaplan–Meier method and the Cox proportional hazards regression model. TG ≤ 1.35, HDL-C ≤ 1.17, and LDL-C ≤ 2.32 were deemed as independent preoperative risk factors for OS, and HDL-C ≤ 1.17 was an independent preoperative risk factor for DFS. In the multivariate analyses involving OS and DFS, a decreased HDL-C level was significantly associated with worse OS (HR, 0.546; 95% CI, 0.380–0.784, P = 0.001) and DFS (HR, 0.644; 95% CI, 0.422–0.981, P = 0.041). Additionally, an increased TG (HR, 0.546; 95% CI, 0.366–0.814, P = 0.003) or LDL-C (HR, 0.652; 95% CI, 0.456–0.933, P = 0.019) level was significantly associated with better OS. In patients with LUSC, decreased levels of HDL-C may predict worse outcomes for both DFS and OS, while increased TG or LDL-C levels may predict better OS.

14 June 2025 in International Immunopharmacology
Verified
Journal Article
Closed access
TZTing Zhu
Ting Zhu
MPMaojie Pan
Maojie Pan
QDQiannan Ding
Qiannan Ding
JDJianyi Ding
Jianyi Ding
BWBin Wang
Bin Wang
YXYangjun Xu
Yangjun Xu

20 November 2025 in Toxicology and Applied Pharmacology
Verified
Journal Article
Closed access
JDJianyi Ding
Jianyi Ding
ZCZhile Chen
Zhile Chen
JYJiaqin Yu
Jiaqin Yu
YXYangjun Xu
Yangjun Xu
TZTing Zhu
Ting Zhu
ACAixia Chen
Aixia Chen

1 April 2025 in Translational Cancer Research
Verified
Journal Article
Open access
PDF file
ZLZhupeng Li
Zhupeng Li
JXJianfeng Xu
Jianfeng Xu
JWJiacheng Wu
Jiacheng Wu
JZJunqing Zhou
Junqing Zhou
HWHaiyong Wang
Haiyong Wang
PXPeng Xu
Peng Xu
Original Article Elevated levels of total cholesterol and high-density lipoprotein cholesterol are associated with better prognosis in patients with lung adenocarcinoma: a retrospective cohort study Zhupeng Li, Jianfeng Xu, Jiacheng Wu, Junqing Zhou, Haiyong Wang, Haixia Xu, Bin Wang, Jianyi Ding, Guangmao Yu, Peng Xu